Jeffrey S. Heier - Oct 2, 2024 Form 3 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)

Role
Chief Scientific Officer
Signature
/s/ Donald Notman, Attorney-in-Fact for Jeffrey S. Heier
Stock symbol
OCUL
Transactions as of
Oct 2, 2024
Transactions value $
$0
Form type
3
Date filed
10/4/2024, 05:17 PM
Previous filing
Aug 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCUL Common Stock 172K Oct 2, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 11.4K $16.64 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 13.5K $12.05 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 13.5K $10.71 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 18K $8.14 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 18K $3.90 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 18K $8.75 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 18K $13.51 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 26.8K $3.43 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 16K $4.25 Direct F3
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 36K $5.31 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 17.4K $4.30 Direct F2
holding OCUL Stock Option (Right to Buy) Oct 2, 2024 Common Stock 367K $9.70 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 101,852 restricted stock units ("RSUs") remaining unvested pursuant to an award of 122,222 RSUs granted under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation") on February 22, 2024. Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal quarterly installments, beginning on the date of grant.
F2 This option is fully vested and exercisable.
F3 This option was granted on October 17, 2022 and vests over four years, with 1/48 of the shares underlying the option vesting monthly beginning on August 1, 2022.
F4 This option was granted on February 22, 2024 and vests over four years, with 1/4 of the shares underlying the option vesting on February 21, 2025 and 1/48 of the shares vesting monthly thereafter.

Remarks:

Exhibit List Exhibit 24 - Power of Attorney